Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Recurrent or Metastatic Malignant Salivary Gland Tumors
NCT00859937Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2009
- Primary completion
- Jan 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of dasatinib in Malignant salivary gland tumor (SGC), adenoid cystic carcinoma (ACC), sponsored by National Cancer Institute. Started Mar 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
Malignant salivary gland tumor (SGC)adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT00859937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00859937.